03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
07:00 , Jun 16, 2016 |  BC Innovations  |  Emerging Company Profile

No cells left behind

Although transplantation of human islets from donated pancreatic tissue is well known to restore insulin production in Type I diabetes patients, there is a severe shortage of donor tissue. Islexa Ltd. has developed a way...
07:00 , Apr 28, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Synthetic biology-based protocol to differentiate human induced pluripotent stem (iPS) cell-derived pancreatic progenitors into mature β-like cells

Drug platforms TECHNOLOGY: Cell therapy A synthetic lineage-control network could program human iPS cell-derived pancreatic progenitor cells into mature β-like cells used to treat diabetes. In human iPS cell-derived pancreatic progenitors, expression of a synthetic...
07:00 , Mar 24, 2016 |  BC Innovations  |  Translation in Brief

Stomaching insulin production

A Harvard University study suggests antral stomach cells share enough features with pancreatic β cells that they can be coached to play the part. The authors think direct reprogramming of this renewable, accessible stomach cell...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: In vivo reprogramming of stomach cells into insulin-secreting pancreatic β-like cells

Drug platforms TECHNOLOGY: Cell therapy Insulin-secreting pancreatic β-like cells derived from renewable stomach cells could help treat diabetes. In mice, gastrointestinal and antral stomach enteroendocrine cells were engineered to express three human genes - neurogenin...
07:00 , Apr 3, 2014 |  BC Innovations  |  Cover Story

Critical mass in diabetes

A University of Bremen group has found a new target-serine/threonine kinase 4-that can increase b cell mass and could represent an alternative to invasive islet cell transplants in patients with diabetes. 1 Next, the team...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Pancreatic and duodenal homeobox 1 (PDX1; IPF1) In vitro studies identified a small molecule that increases PDX1 expression and could help treat diabetes....
07:00 , Aug 22, 2011 |  BioCentury  |  Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Endocrine disease Diabetes Peptidylprolyl isomerase F (PPIF; cyclophilin D); pancreatic and duodenal homeobox 1 (PDX1; IPF1) Mouse studies suggest that inhibiting cyclophilin D in diabetic patients with dysfunctional PDX1 could help treat the condition. Genetic...
08:00 , Feb 18, 2010 |  BC Innovations  |  Tools & Techniques

Bypassing the iPS logjam

Researchers at the Stanford University School of Medicine have found a way to efficiently convert mouse fibroblasts into functional neurons without first reverting the skin cells to a pluripotent state. 1 The protocol could make...